Skip to main content

Advertisement

SpringerLink
Log in

Podoplanin—a novel marker in oral carcinogenesis

  • Review
  • Published:
Tumor Biology

Abstract

Podoplanin, a transmembrane sialoglycoprotein, is a specific marker for lymphatic endothelial cells which in recent years has gained prominent notoriety for its role in tumor progression and metastasis. It is an extensively studied biomarker for predictive assessment of malignant transformation as well as biologic behavior in both human precancer and cancer, respectively. This review summarizes the association of podoplanin overexpression in oral potentially malignant disorders and oral cancer with special emphasis on its putative role in carcinogenesis as well as its prospective use in targeted therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Matsui K, Breitender-Geleff S, Soleiman A, Kowalski H, Kerjaschki D. Podoplanin, a novel 43-kDa membrane protein, controls the shape of podocytes. Nephrol Dial Transplant. 1999;14:9–11.

    Article  CAS  PubMed  Google Scholar 

  2. Schacht V, Dadras SS, Johnson LA, Jackson DG, Hong YK, Detmar M. Up-regulation of the lymphatic marker podoplanin, a mucin-type transmembrane glycoprotein, in human squamous cell carcinoma and germ cell tumors. Am J Pathol. 2005;166(3):913–21.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  3. Kaneko MK, Kato Y, Kitano T, Osawa M. Conservation of a platelet activating domain of Aggrus/podoplanin as a platelet aggregation-inducing factor. Gene. 2006;378:52–7.

    Article  CAS  PubMed  Google Scholar 

  4. Kanekoa MK, Yukinari K, Kameyama A, Ito H, Kuno A, Hirabayashi J, et al. Functional glycosylation of human podoplanin: glycan structure of platelet aggregation-inducing factor. FEBS Lett. 2007;581(2):331–6.

    Article  Google Scholar 

  5. Ariizumi T, Ogose A, Kawashima H, Hotta T, Li G, Xu Y, et al. Expression of podoplanin in human bone and bone tumors: new marker of osteogenic and chondrogenic bone tumors. Pathol Int. 2010;60(3):193–202.

    Article  CAS  PubMed  Google Scholar 

  6. Imaizumi Y, Amano I, Tsuruga E, Kojima H, Sawa Y. Immunohistochemical examination for the distribution of podoplanin-expressing cells in developing mouse molar tooth germs. Acta Histochem Cytochem. 2010;43(5):115–21.

    Article  PubMed Central  PubMed  Google Scholar 

  7. Bhalla R, Siddiqui MT, Mandich D, Cartun RW, Fiel-Gan MD, Nassar A. Diagnostic utility of D2-40 and podoplanin in effusion cell blocks. Diagn Cytopathol. 2007;35(6):342–7.

    Article  PubMed  Google Scholar 

  8. Honma M, Minami-Hori M, Takahashi H, Iizuka H. Podoplanin expression in wound and hyperproliferative psoriatic epidermis: regulation by TGF-β and STAT-3 activating cytokines, IFN-γ, IL-6, and IL-22. J Dermatol Sci. 2012;65(2):134–40.

    Article  CAS  PubMed  Google Scholar 

  9. Kanner WA, Galgano MT, Atkins KA. Podoplanin expression in basal and myoepithelial cells: utility and potential pitfalls. Appl Immunohistochem Mol Morphol. 2010;18(3):226–30.

    Article  CAS  PubMed  Google Scholar 

  10. Kaji C, Tomooka M, Kato Y, Kojima H, Sawa Y. The expression of podoplanin and classic cadherins in the mouse brain. J Anat. 2012;220(5):435–46.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  11. Breiteneder-Geleff S, Matsui K, Soleiman A, Meraner P, Poczewski H, Kalt R, et al. Podoplanin, novel 43-kd membrane protein of glomerular epithelial cells, is down-regulated in puromycin nephrosis. Am J Pathol. 1997;151(4):1141–52.

    PubMed Central  CAS  PubMed  Google Scholar 

  12. Raica M, Cimpean AM, Ribatti D. The role of podoplanin in tumor progression and metastasis. Anticancer Res. 2008;28(5B):2997–3006.

    PubMed  Google Scholar 

  13. Yu H, Gibson JA, Pinkus GS, Hornick JL. Podoplanin (D2-40) is a novel marker for follicular dendritic cell tumors. Am J Clin Pathol. 2007;128(5):776–82.

    Article  PubMed  Google Scholar 

  14. Zayed AE, Abd-Elnaeim MM, Abd-Elghaffar SK, Hild A, Brehm R, Steger K. Prenatal development of murine gonads with special reference to germ cell differentiation: a morphological and immunohistochemical study. Andrologia. 2007;39(3):93–100.

    Article  CAS  PubMed  Google Scholar 

  15. Mahtab EAF, Wijffels MCEF, Van Den Akker NMS, Hahurij ND, Lie-Venema H, Wisse LJ, et al. Cardiac malformations and myocardial abnormalities in podoplanin knockout mouse embryos: correlation with abnormal epicardial development. Dev Dyn. 2008;237(3):847–57.

    Article  CAS  PubMed  Google Scholar 

  16. Ramirez MI, Millien G, Hinds A, Cao Y, Seldin DC, Williams MC. T1alpha, a lung type I cell differentiation gene, is required for normal lung cell proliferation and alveolus formation at birth. Dev Biol. 2003;256(1):61–72.

    Article  CAS  PubMed  Google Scholar 

  17. Uhrin P, Zaujec J, Breuss JM, Olcaydu D, Chrenek P, Stockinger H, et al. Novel function for blood platelets and podoplanin in developmental separation of blood and lymphatic circulation. Blood. 2010;115:3997–4005.

    Article  CAS  PubMed  Google Scholar 

  18. Hong Y-K, Harvey N, Noh Y-H, Schacht V, Hirakawa S, Detmar M, et al. Prox1 is a master control gene in the program specifying lymphatic endothelial cell fate. Dev Dyn. 2002;225:351–7.

    Article  CAS  PubMed  Google Scholar 

  19. Gröger M, Loewe R, Holnthoner W, Embacher R, Pillinger M, Herron GS, et al. IL-3 induces expression of lymphatic markers Prox-1 and podoplanin in human endothelial cells. J Immunol. 2004;173:7161–9.

    Article  PubMed  Google Scholar 

  20. Kunita A, Kashima TG, Ohazama A, Grigoriadis AE, Fukayama M. Podoplanin is regulated by AP-1 and promotes platelet aggregation and cell migration in osteosarcoma. Am J Pathol. 2011;179:1041–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  21. Ekwall A-KH, Eisler T, Anderberg C, Jin C, Karlsson N, Brisslert M, et al. The tumour-associated glycoprotein podoplanin is expressed in fibroblast-like synoviocytes of the hyperplastic synovial lining layer in rheumatoid arthritis. Arthritis Res Ther. 2011;13:R40.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  22. Ohta M, Abe A, Ohno F, Hasegawa Y, Tanaka H, Maseki S. Positive and negative regulation of podoplanin expression by TGF-β and histone deacetylase inhibitors in oral and pharyngeal squamous cell carcinoma cell lines. Oral Oncol. 2013;49:20–6.

    Article  CAS  PubMed  Google Scholar 

  23. Brigitte H, Kalt R, Krieger S, Puri C, Kerjaschki D. Sp1/Sp3 and DNA-methylation contribute to basal transcriptional activation of human podoplanin in MG63 versus Saos-2 osteoblastic cells. BMC Mol Biol. 2007. doi:10.1186/1471-2199-8-20.

    Google Scholar 

  24. Inoue H, Miyazaki Y, Kikuchi K, Yoshida N, Ide F, Ohmori Y, et al. Podoplanin promotes cell migration via the EGF-Src-Cas pathway in oral squamous cell carcinoma cell lines. J Oral Sci. 2012;54:241–50.

    Article  CAS  PubMed  Google Scholar 

  25. Shen Y, Chen CS, Ichikawa H, Goldberg GS. SRC induces podoplanin expression to promote cell migration. J Biol Chem. 2010;285:9649–56.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  26. Atsumi N, Ishii G, Kojima M, Sanada M, Fujii S, Ochiai A. Podoplanin, a novel marker of tumor-initiating cells in human squamous cell carcinoma A431. Biochem Biophys Res Commun. 2008;373:36–41.

    Article  CAS  PubMed  Google Scholar 

  27. Durchdewald M, Guinea-Viniegra J, Haag D, Riehl A, Lichter P, Hahn M, et al. Podoplanin is a novel fos target gene in skin carcinogenesis. Cancer Res. 2008;68:6877–83.

    Article  CAS  PubMed  Google Scholar 

  28. Hirao M, Sato N, Kondo T, Yonemura S, Monden M, Sasaki T, et al. Regulation mechanism of ERM (ezrin/radixin/moesin) protein/plasma membrane association: possible involvement of phosphatidylinositol turnover and Rho-dependent signaling pathway. J Cell Biol. 1996;135:37–51.

    Article  CAS  PubMed  Google Scholar 

  29. Martín-Villar E, Megías D, Castel S, Yurrita MM, Vilaró S, Quintanilla M. Podoplanin binds ERM proteins to activate RhoA and promote epithelial-mesenchymal transition. J Cell Sci. 2006;119:4541–53.

    Article  PubMed  Google Scholar 

  30. Wicki A, Lehembre F, Wick N, Hantusch B, Kerjaschki D, Christofori G. Tumor invasion in the absence of epithelial-mesenchymal transition: podoplanin-mediated remodeling of the actin cytoskeleton. Cancer Cell. 2006;9:261–72.

    Article  CAS  PubMed  Google Scholar 

  31. Wicki A, Christofori G. The potential role of podoplanin in tumour invasion. Br J Cancer. 2007;96:1–5.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  32. Martín-Villar E, Fernández-Muñoz B, Parsons M, Yurrita MM, Megías D, Pérez-Gómez E, et al. Podoplanin associates with CD44 to promote directional cell migration. Mol Biol Cell. 2010;21:4387–99.

    Article  PubMed Central  PubMed  Google Scholar 

  33. Lowe KL, Navarro-Nunez L, Watson SP. Platelet CLEC-2 and podoplanin in cancer metastasis. Thromb Res. 2012;129:S30–7.

    Article  CAS  PubMed  Google Scholar 

  34. Suzuki-Inoue K, Kato Y, Inoue O, Kaneko MK, Mishima K, Yatomi Y, et al. Involvement of the snake toxin receptor CLEC-2, in podoplanin-mediated platelet activation, by cancer cells. J Biol Chem. 2007;282:25993–6001.

    Article  CAS  PubMed  Google Scholar 

  35. Kitano H, Kageyama S-I, Hewitt SM, Hayashi R, Doki Y, Ozaki Y, et al. Podoplanin expression in cancerous stroma induces lymphangiogenesis and predicts lymphatic spread and patient survival. Arch Pathol Lab Med. 2010;134:1520–7.

    CAS  PubMed  Google Scholar 

  36. Neri S, Ishii G, Taira T, Hishida T, Yoshida J, Nishimura M, et al. Recruitment of podoplanin positive cancer-associated fibroblasts in metastatic lymph nodes predicts poor prognosis in pathological N2 stage III lung adenocarcinoma. Ann Surg Oncol. 2012;19:3953–62.

    Article  PubMed  Google Scholar 

  37. Pula B, Jethon A, Piotrowska A, Gomulkiewicz A, Owczarek T, Calik J, et al. Podoplanin expression by cancer-associated fibroblasts predicts poor outcome in invasive ductal breast carcinoma. Histopathology. 2011;59:1249–60.

    Article  PubMed  Google Scholar 

  38. Hoshino A, Ishii G, Ito T, Aoyagi K, Ohtaki Y, Nagai K, et al. Podoplanin-positive fibroblasts enhance lung adenocarcinoma tumor formation: podoplanin in fibroblast functions for tumor progression. Cancer Res. 2011;71:4769–79.

    Article  CAS  PubMed  Google Scholar 

  39. Ito S, Ishii G, Hoshino A, Hashimoto H, Neri S, Kuwata T, et al. Tumor promoting effect of podoplanin-positive fibroblasts is mediated by enhanced RhoA activity. Biochem Biophys Res Commun. 2012;422:194–9.

    Article  CAS  PubMed  Google Scholar 

  40. Yamanashi T, Nakanishi Y, Fujii G, Akishima-Fukasawa Y, Moriya Y, Kanai Y, et al. Podoplanin expression identified in stromal fibroblasts as a favorable prognostic marker in patients with colorectal carcinoma. Oncology. 2009;77:53–62.

    Article  CAS  PubMed  Google Scholar 

  41. Astarita JL, Acton SE, Turley SJ. Podoplanin: emerging functions in development, the immune system, and cancer. Front Immunol. 2012;3:283. doi:10.3389/fimmu.2012.00283.

    Article  PubMed Central  PubMed  Google Scholar 

  42. Kawaguchi H, El-Naggar AK, Papadimitrakopoulou V, Ren H, Fan YH, Feng L, et al. Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy. J Clin Oncol. 2008;26:354–60.

    Article  PubMed  Google Scholar 

  43. Zhang G, Guo ZL, Gao Y. Podoplanin expression in oral squamous cell carcinoma and leukoplakia and its correlation with lymph vessels density. Zhonghua Kou Qiang Yi Xue Za Zhi. 2009;44:488–91.

    PubMed  Google Scholar 

  44. de Vicente JC, Rodrigo JP, Rodriguez-Santamarta T, Lequerica-Fernández P, Allonca E, García-Pedrero JM. Podoplanin expression in oral leukoplakia: tumorigenic role. Oral Oncol. 2013;49:598–603.

    Article  PubMed  Google Scholar 

  45. Kreppel M, Kreppel B, Drebber U, Wedemayer I, Rothamel D, Zöller JE, et al. Podoplanin expression in oral leukoplakia: prognostic value and clinicopathological implications. Oral Dis. 2012;18:692–9.

    Article  CAS  PubMed  Google Scholar 

  46. Feng JQ, Mi JG, Wu L, Ma LW, Shi LJ, Yang X, et al. Expression of podoplanin and ABCG2 in oral erythroplakia correlate with oral cancer development. Oral Oncol. 2012;48:848–52.

    Article  CAS  PubMed  Google Scholar 

  47. Funayama A, Cheng J, Maruyama S, Yamazaki M, Kobayashi T, Syafriadi M, et al. Enhanced expression of podoplanin in oral carcinomas in situ and squamous cell carcinomas. Pathobiology. 2011;78:171–80.

    Article  CAS  PubMed  Google Scholar 

  48. Shi P, Liu W, Zhou ZT, He QB, Jiang WW. Podoplanin and ABCG2: malignant transformation risk markers for oral lichen planus. Cancer Epidemiol Biomarkers Prev. 2010;19:844–9.

    Article  CAS  PubMed  Google Scholar 

  49. Shimamura Y, Abe T, Nakahira M, Yoda T, Murata S, Sugasawa M. Immunohistochemical analysis of oral dysplasia: diagnostic assessment by fascin and podoplanin expression. Acta Histochem Cytochem. 2011;44:239–45.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  50. Martin-Villar E, Scholl FG, Gamallo C, Yurrita MM, Muñoz-Guerra M, Cruces J, et al. Characterization of human PA2.26 antigen (T1alpha-2, podoplanin), a small membrane mucin induced in oral squamous cell carcinomas. Int J Cancer. 2005;113(6):899–910.

    Article  CAS  PubMed  Google Scholar 

  51. Yuan P, Temam S, El-Naggar A, Zhou X, Liu DD, Lee JJ, et al. Overexpression of podoplanin in oral cancer and its association with poor clinical outcome. Cancer. 2006;107(3):563–9.

    Article  CAS  PubMed  Google Scholar 

  52. Kreppel M, Scheer M, Drebber U, Ritter L, Zöller JE. Impact of podoplanin expression in oral squamous cell carcinoma: clinical and histopathologic correlations. Virchows Arch. 2010;456(5):473–82.

    Article  CAS  PubMed  Google Scholar 

  53. dos Santos AA, Oliveira DT, Pereira MC, Faustino SE, Nonogaki S, Carvalho AL, et al. Podoplanin and VEGF-C immunoexpression in oral squamous cell carcinomas: prognostic significance. Anticancer Res. 2013;33(9):3969–76.

    Google Scholar 

  54. Zhao D, Pan J, Li XQ, Wang XY, Tang C, Xuan M. Intratumoral lymphangiogenesis in oral squamous cell carcinoma and its clinicopathological significance. J Oral Pathol Med. 2008;37(10):616–25.

    Article  CAS  PubMed  Google Scholar 

  55. de Sousa SF, Gleber-Netto FO, de Oliveira-Neto HH, Batista AC, Nogueira Guimarães Abreu MH, de Aguiar MC. Lymphangiogenesis and podoplanin expression in oral squamous cell carcinoma and the associated lymph nodes. Appl Immunohistochem Mol Morphol. 2012;20(6):588–94.

    Article  PubMed  Google Scholar 

  56. Muñoz-Guerra MF, Marazuela EG, Martín-Villar E, Quintanilla M, Gamallo C. Prognostic significance of intratumoral lymphangiogenesis in squamous cell carcinoma of the oral cavity. Cancer. 2004;100(3):553–60.

    Article  PubMed  Google Scholar 

  57. Kyzas PA, Geleff S, Batistatou A, Agnantis NJ, Stefanou D. Evidence for lymphangiogenesis and its prognostic implications in head and neck squamous cell carcinoma. J Pathol. 2005;206(2):170–7.

    Article  PubMed  Google Scholar 

  58. Ohno F, Nakanishi H, Abe A, Seki Y, Kinoshita A, Hasegawa Y, et al. Regional difference in intratumoral lymphangiogenesis of oral squamous cell carcinomas evaluated by immunohistochemistry using D2-40 and podoplanin antibody: an analysis in comparison with angiogenesis. J Oral Pathol Med. 2007;36(5):281–9.

    Article  PubMed  Google Scholar 

  59. Ochoa-Alvarez JA, Krishnan H, Shen Y, Acharya NK, Han M, et al. Plant lectin can target receptors containing sialic acid, exemplified by podoplanin, to inhibit transformed cell growth and migration. PLoS ONE. 2012;7(7):e41845. doi:10.1371/journal.pone.0041845.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  60. Chandramohan V, Bao X, Kato KM, Kato Y, Keir ST, Szafranski SE, et al. Recombinant anti-podoplanin (NZ-1) immunotoxin for the treatment of malignant brain tumors. Int J Cancer. 2013;132(10):2339–48.

    Article  CAS  PubMed  Google Scholar 

  61. Takagi S, Sato S, Oh-hara T, Takami M, Koike S, et al. Platelets promote tumor growth and metastasis via direct interaction between Aggrus/podoplanin and CLEC-2. PLoS ONE. 2013;8(8):e73609. doi:10.1371/journal.pone.0073609.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  62. Cueni LN et al. Podoplanin-Fc reduces lymphatic vessel formation in vitro and in vivo and causes disseminated intravascular coagulation when transgenically expressed in the skin. Blood. 2010;116(20):4376–84.

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Author’s contribution

All authors have contributed equally in preparation of the manuscript.

Conflicts of interest

None

Role of funding source

None

Ethics committee approval

Not applicable

Author information

Authors and Affiliations

  1. Department of Oral Pathology, MGM Dental College and Hospital, 304, Siddhi Vinayak Residency Sector 9, Plot no. 40 Kamothe, Navi Mumbai, 410209, Maharashtra, India

    Niharika Swain, Shwetha V. Kumar, Jigna Pathak & Shilpa Patel

  2. Department of Oral Pathology, Institute of Dental Sciences, Siksha ‘O’ Anusandhan University, Bhubaneswar, Odisha, India

    Samapika Routray

Authors
  1. Niharika Swain
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shwetha V. Kumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Samapika Routray
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jigna Pathak
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shilpa Patel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Niharika Swain.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Swain, N., Kumar, S.V., Routray, S. et al. Podoplanin—a novel marker in oral carcinogenesis. Tumor Biol. 35, 8407–8413 (2014). https://doi.org/10.1007/s13277-014-2266-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-014-2266-5

Keywords

Search

Navigation